

KELLER AND HECKMAN LLP
SERVING BUSINESS THROUGH LAW AND SCIENCE®

1001 G STREET, N. W.
SUITE 500 WEST
WASHINGTON, D.C. 20001
TEL 202.434.4100
FAX 202.434.4646
WWW.KHLAW.COM

1822 '03 SEP -8 P2:26

WRITER'S DIRECT ACCESS

September 8, 2003

John B. Dubeck
(202) 434-4125
Dubeck@khlaw.com

Via Hand Delivery

Dockets Management Branch (HFA-305)
Food and Drug Administration
Room 1061
5630 Fishers Lane
Rockville, MD 20852


Re: Docket No. 2003N00324; Notice of Participation and Request for Hearing

Dear Sir or Madam:

In the *Federal Register* of August 8, 2003, FDA published a notice of opportunity for hearing with respect to the Agency's proposal to withdraw various new animal drug applications (NADAs) for certain products or use combinations lacking substantial evidence of effectiveness, as well as "all issues relating to the legal status of the drug products subject to" the notice. Alparma Inc. (Alparma) hereby requests a hearing pursuant to this notice.

Alparma will submit data, information, and analyses in support of this request for a hearing on or before October 7, 2003.

Respectfully submitted,


John B. Dubeck
Frederick A. Stearns
Keller and Heckman LLP
1001 G Street, N.W., Suite 500W
Washington, D.C. 20001
(202) 434-4200

Counsel for Alparma Inc.

2003N-0324/B

HERG

WASHINGTON, D.C.

BRUSSELS

SAN FRANCISCO